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Abstract
Background: A corollary of the reserve hypothesis is that 
what is regarded as pathological cortical metabolism in pa-
tients might vary according to education. Objective: The aim 
of this study is to assess the incremental diagnostic value of 
education-adjusted over unadjusted thresholds on the diag-
nostic accuracy of FDG-PET as a biomarker for Alzheimer dis-
ease (AD). Methods: We compared cortical metabolism in 90 
healthy controls and 181 AD patients from the Alzheimer 
Disease Neuroimaging Initiative (ADNI) database. The AUC 
of the ROC curve did not differ significantly between the 
whole group and the higher-education patients or the low-
er-education subjects. Results: The threshold of wMetaROI 
values providing 80% sensitivity was lower in higher-educa-
tion patients and higher in the lower-education patients, 
compared to the standard threshold derived over the whole 
AD collective, without, however, significant changes in sen-
sitivity and specificity. Conclusion: These data show that ed-
ucation, as a proxy of reserve, is not a major confounder in 
the diagnostic accuracy of FDG-PET in AD and the adoption 
of education-adjusted thresholds is not required in daily 
practice. © 2018 S. Karger AG, Basel
Introduction
The concept of reserve in Alzheimer disease (AD) has 
been introduced to explain the dissociation between the ex-
tent of the underlying AD pathology and the clinical ex-
pression of dementia [1, 2]. Reserve is conceptualized ei-
ther in the form of neuronal/brain reserve or in the form of 
cognitive reserve, or compensation, thanks to neurocom-
putational flexibility and/or intellectual competence [3].
Multiple proxies, such as measures of intelligence, 
years of schooling, occupational nature and complexity, 
Data analyzed in this article were obtained from the Alzheimer’s Dis-
ease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). 
The ADNI investigators contributed to the design and implementa-
tion of ADNI and/or provided data but did not participate in these 
analyses or this paper. A complete listing of ADNI investigators can 





















   
   
   
   
   
   
   
   
   
   
























and intellectual activities during leisure time, have been 
used to assess the degree of reserve [3–7]. Years of formal 
education, being easily quantifiable, is the proxy most 
commonly used.
FDG-PET (PET with 18F-fluorodeoxyglucose) is a 
sensitive and specific imaging biomarker for the diagno-
sis of AD and the best predictor of progression to demen-
tia in mild cognitive impairment [8–11].
Values for sensitivity and specificity are quite variable, 
depending on disease severity as well as on the specific 
metric used, but the overall performance of the test is 
good, with a median sensitivity and specificity of 80 and 
72.5%, respectively [9, 10].
Subjects with a higher reserve who are able to cope 
with a higher degree of pathology exhibit a more pro-
nounced decrease in metabolism of the regions typically 
affected compared to patients with lower reserve for a 
comparable level of clinical impairment [4, 6, 7]. How-
ever, the extent of this difference and its potential impact 
on the diagnostic use of the test is not currently known.
The aim of this study was to evaluate the impact of 
years of education, as a proxy of reserve, on the diagnostic 
accuracy of FDG-PET as a biomarker for AD and the 
threshold of FDG hypometabolism that should be con-




This study included 90 healthy controls (HC) and 181 AD 
patients selected from the Alzheimer’s Disease Neuroimaging 
(ADNI) database (adni.loni.usc.edu). The ADNI is a public-pri-
vate partnership launched in 2003 and led by Michael W. Weiner, 
focused on testing the value of various imaging and biological 
markers for the diagnosis of mild cognitive impairment and early 
AD. For up-to-date information, see www.adni-info.org.
We included all of the baseline PET scans of patients with a di-
agnosis of HC or AD available from the ADNI1 study in the pre-
processed form (coregistered, averaged, standardized image and 
voxel size, uniform resolution), with a standard procedure de-
scribed at http://adni.loni.usc.edu/methods/pet-analysis/pre-pro-
cessing/. PET data and data on the clinical diagnosis, global func-
tioning (measured using the Mini Mental State Examination 
[MMSE] score) years of education, age, and FDG-PET scans were 
extracted in December 2016. We excluded HC for which a subse-
quent follow-up evaluation showed progression to mild cognitive 
impairment or AD.
FDG-PET Processing 
In order to characterize each subject, a summary metric of hy-
pometabolism at the sites typically affected by AD, i.e., the Meta-
ROI set, was used [12]. Briefly, this index is computed with extrac-
tion of the mean activity in a set of 5 predefined ROI (bilateral 
angular gyrus, posterior cingulum, and bilateral inferior temporal 
gyrus), normalized to the mean activity of the pons and the cere-
bellar vermis (as defined in the WFUpickatlas SPM toolbox) and 
then corrected for age, calculating the wMetaROI scores, as previ-
ously tested [13]. The resulting wMetaROI score for each subject 
was then used for the subsequent analyses. 
In addition, adjustment of the wMetaROI score to the respec-
tive MMSE was conducted, adopting the same procedure used for 
age, in order to control for the possible effect of a different level of 
cognitive impairment between patients. 
Statistical Analyses
For descriptive statistics of the characteristics of the popula-
tion, we used a t test. 
The receiver operating characteristic (ROC) curve approach 
was used to compare the diagnostic accuracy of FDG-PET ob-
tained collectively and in population subgroups defined on the ba-
sis of educational attainment. 
We first dichotomized the AD population into 2 subgroups us-
ing the median value as a cut-off as follows: < 16 years for patients 
with a lower reserve (n = 75) and ≥16 years for patients with a 
higher reserve (n = 106). Lastly, we repeated the same analysis by 
taking into consideration only the extremes of educational attain-
ment, i.e., the 1st and 4th quartiles of the distribution, meaning 
≤13 years for a lower reserve (n = 52) and ≥18 years for a higher 
reserve (n = 55). The area under the curve (AUC) values of the 
ROC curves were compared using a t test. The analysis was repeat-
ed after MMSE adjustment of the wMetaROI scores. 
For the whole population as well as for subgroups defined on 
the basis of education, we calculated the cut-off that maximized 
specificity at a minimal sensitivity of 80%. 
We tested the use of a standard versus an education-adjusted 
threshold, calculating the number of false negatives (FN) and false 
positives (FP) associated with the change in threshold and com-
paring sensitivities and specificities (McNemar test).
We also tested the use of education-adjusted thresholds in the 
whole population to estimate the impact of an index derived from 
a highly or less educated population on a heterogeneous sample 
using the McNemar test. 
We performed a power analysis using PASS 2005 software 
(NCSS, PASS and GESS; NCSS, Kaysville, UT, USA) to estimate 
the sample size necessary to identify a difference of 0.1 in the AUC 
of the ROC curves. The 0.1 difference between AUC was chosen 
Table 1. Characteristics of the patients and HC
Characteristic HC (n = 90) AD (n = 181) p value1
Age, years 75.4±4.7 (62 to 87) 75.6±7 (55 to 88) 0.82
Male/female ratio 55/35 110/71
Education, years 15.8±3.2 (7 to 20) 15.3±3.1 (4 to 20) 0.18
MMSE score 28.9±1.2 (25 to 30) 25.1±2.6 (18 to 30) <0.001
wMetaROI score 1.87±1 (–0.5 to 4.6) 0.4±1.19 (–4.0 to 3.2) <0.001
Values are presented as means ± SD (range). MMSE, Mini Mental State 
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with reference to well-established ranges for the AUC of a diagnos-
tic test as follows: 1–0.9, excellent; 0.9–0.8, good; and 0.8–0.7, fair. 
A population of 56 cases against 90 controls would allow achieve-
ment of 80% power to detect this difference at a significance level 
of 0.05 (one-tailed). 
Results
The characteristics of the study sample and lower-ed-
ucation (LE) and higher-education (HE) subgroups are 
presented in Tables 1 and 2. 
As expected, AD subjects had a lower MMSE score 
(p < 0.001,two-tailed t test) and wMetaROI (p < 0.001) 
compared to HC, with no statistically significant differ-
ence in years of education (p = 0.18) or age (Table 1). 
When dichotomizing the population with respect to 
median education, subjects with an LE had a lower MMSE 
score (p < 0.01; Table 2). This was also true when compar-
ing the two extremes, i.e., LE and HE subjects (p = 0.01; 
Table 3). 
There was a trend, albeit a nonsignificant one (p = 
0.09), toward a lower wMetaROI score in HE patients 
compared to LE patients despite a higher MMSE, as ex-
pected from a higher reserve capacity (Table 3). 
The AUC of the ROC curve of wMetaROI values to 
discriminate the whole AD population from HC was 
0.832. The cut-off value of the wMetaROI score providing 
a minimum of 80% sensitivity was 1.38 (sensitivity 80% 
and specificity 68%).
The AUC of the ROC curve was 0.831 in AD patients 
with a lower reserve (< 16 years) compared to controls and 
0.833 in AD patients with a higher reserve (≥16 years; 
Fig.  1). A t test comparison of the AUC of the 2 ROC 
curves showed that the difference was not significant (p = 
0.96). The cut-off value of the wMetaROI score was 1.38 
in subjects with a lower reserve (sensitivity 80% and spec-
ificity 68%) and 1.37 in subjects with a higher reserve 
(sensitivity 80% and specificity 68%). 
Taking into consideration only the extremes of educa-
tional attainment, the AUC of the ROC curve was 0.816 
Table 2. Descriptive statistics of LE (<16 years) and HE (≥16 years) patients











(HE vs. LE) 
Age, years 76.3±6.6 (58 to 88) 0.32 75.1±7.3 (55 to 88) 0.74 0.26
Male/female ratio 38/37 72/34
Education, years 12.2±2.1 (4 to 15) 17.4±1.5 (16 to 20)
MMSE score 24.4±2.5 (20 to 30) <0.001 25.5±2.6 (18 to 30) <0.001 <0.01
wMetaROI score 0.4±1.1 (–2.3 to 2.2) <0.001 0.37±1.3 (–4.0 to 3.2) <0.001 0.7
Values are presented as means ± SD (range). MMSE, Mini Mental State Examination; LE, lower education; 
HE, higher education; HC, healthy controls. 1 Two-tailed t test.
Table 3. Descriptive statistics of LE (≤13 years) and HE (≥18 years) patients












Age, years 77.2±6.6 (59 to 88) 0.06 74.8±7.6 (55 to 88) 0.53 0.08
Male/female ratio 23/29 37/18
Education, years 11.4±1.9 (4 to 13) 18.6±0.9 (18 to 20)
MMSE score 24.4±2.5 (20 to 30) <0.001 25.7±2.6 (20 to 30) <0.001 0.01
wMetaROI score 0.6±1 (–1.8 to 2.2) <0.001 0.27±1.1 (–2.8 to 2.1) <0.001 0.09
Values are presented as means ± SD (range). MMSE, Mini Mental State Examination; LE, lower education; 




















   
   
   
   
   
   
   
   
   
   
























when analyzing only LE AD patients compared to con-
trols, and 0.861 in HE AD patients (Fig. 2). A t test com-
parison of the AUC of the 2 ROC curves showed that this 
difference was not significant (p = 0.39). The cut-off value 
of the wMetaROI score was 1.5 for LE subjects (sensitiv-
ity 81% and specificity 66%) and 1.2 for HE subjects (sen-
sitivity 80% and specificity 73%). 
No significant difference was found between the AUC 
of the ROC curves for the whole AD collectively and the 
LE subgroup (p = 0.73) or between the AUC for the whole 
AD population and the HE subgroup (p = 0.49).
When applying the standard cut-off calculated for the 
whole AD population (i.e., 1.38) in the LE subgroup in-
stead of the education-adjusted threshold (i.e., 1.5), there 
was no significant difference in sensitivity (p = 1) or spec-
ificity (p = 1). The use of an education-adjusted threshold 
avoided 1 FN but implied 1 additional FP. When applying 
the standard cut-off in the HE subgroup, instead of the 
education-adjusted cut-off (i.e., 1.2), there was no signif-
icant change in sensitivity (p = 0.25) or specificity (p = 
0.063); the use of an education-adjusted cut-off implied 3 
FN and avoided 5 FP findings. 
Finally, there was a trend for a higher sensitivity (p = 
0.063) and no significant difference in specificity (p = 1) 
when using the education-adjusted threshold for LE for 
the whole population; this change in threshold induced 1 
FP and avoided 5 FN. 
When using the cut-off obtained for the HE subgroup 
in the whole population, there was a significant decrease 
in sensitivity (p = 0.004) with a limited gain in specificity 
which did not reach significance (p = 0.063), implying 9 
FN and correcting 5 FP.
Table 4 summarizes these results. Table 5 reports the 
results for the wMetaROI scores corrected for the effect 
of MMSE, confirming that the diagnostic performance of 
the test does not differ on the basis of education level. 
Discussion
We specifically tested whether the diagnostic accuracy 
is different in subgroups with higher and lower reserve 
capacities, as measured by years of education, and the 














Fig. 1. Receiver operating characteristic curves of 18F-FDG-PET 
in the whole AD population (black) against AD patients with low-














Fig. 2. Receiver operating characteristic curves of 18F-FDG-PET 
in the whole AD collective (black) against the subgroups of ex-
treme educational attainment, i.e., ≤13 years for patients with a 

















































   
   
   
   
   
   
   
   
   
   




















Mainta et al.Neurodegener Dis 2018;18:120–126124
DOI: 10.1159/000488915
cation-adjusted thresholds with respect to a threshold de-
fined over an “educationally heterogeneous” population. 
FDG-PET is largely used as a disease and progression 
biomarker in AD. The evidence for the clinical validity of 
different biomarkers for dementia in AD, including FDG-
PET, has been recently revised in a validation framework 
derived from oncology [11, 14–16]. One secondary aim 
of phase 2 of the validation process, which concerns the 
use of the assay in the clinical disease phase, is the assess-
ment of factors associated with biomarker status or level 
in control subjects and in patients. Factors known to af-
fect the biomarker should be tested for their impact on 
test positivity to define the need of having a factor-adjust-
ed threshold in target subpopulations. While multiple 
previous studies have shown that education has an im-
pact on the severity of metabolic impairment in AD sub-
jects, this is the first study, to the best of our knowledge, 
to estimate the impact of the reserve phenomenon on the 
use of FDG-PET as diagnostic biomarker of AD in terms 
of diagnostic accuracy and normality threshold. 
More educated individuals present at diagnosis with a 
more severe metabolic impairment the functional impact 
of which is compensated by the reserve capacity both in 
clinical [17, 18] and in preclinical AD [4, 7]. An individ-
ual example of the more extensive metabolism observed 
in patients with a higher reserve is provided in Figure 3.
Our results are in line with these findings, showing 
lower, albeit not significant, wMetaROI scores in patients 
with a higher reserve, despite a higher MMSE score, sug-
gestive of relative compensation in a more advanced stage 
of the disease. Consistently, there was also an impact of 
reserve on the threshold to obtain 80% sensitivity, i.e., a 
less stringent threshold for LE subjects. It should be noted 
that the educational level of our sample was relatively 
high, and thus the estimates derived from this population 
might underestimate the impact of education with re-
spect to a more representative memory clinic population.
However, this difference did not impact the diagnostic 
accuracy of the test, which was equally high in the whole 
population and in the LE and HE subgroups, which rep-
resent by definition the extremes of the distribution. In 
addition, the change in specificity was not statistically sig-
nificant when the threshold derived from the general AD 
population was applied in the subgroups of LE and HE 
individuals. Overall, education was not a confounder in 
the diagnostic accuracy of FDG-PET in AD.
The set of 5 predefined ROI included in the metaROI 
targets the regions typically affected by AD but not neces-
sarily the regions most touched by reserve phenomena. 
Differences between LE and HE have been consistently 
observed, occurring also in regions outside those consid-
ered by the metaROI. In a study of 242 patients and 144 
controls, the authors found a significant impact of educa-
tion and occupation on the metabolic activity in the pos-
terior temporoparietal cortex, the precuneus, and the pre-
motor/prefrontal cortex [7]. Other studies have also 
shown significant associations in the ventral prefrontal 
metabolism [4] and in the right dorsolateral prefrontal 
cortex [6]. 
The association between reserve and the proxy we used 
has some limitations. Indeed, years of formal education 
are able to capture only partly the phenomena associated 
with the reserve capacity, and multiple other proxies, e.g., 
occupational complexity and leisure activity, contribute 
independently to the development of reserve [19]. It is 
possible that in the LE population we misclassified some 
subjects having a higher reserve capacity provided by oth-
er factors not related to education. Ideally, composite 
measures taking into account, in addition to years of edu-
cation, various factors such as measures of intelligence, 
nature and complexity of occupation, and intellectual ac-
tivities during leisure time would serve best as surrogate 









Whole AD 0.832 1.38 80 68
LE AD <16 years 0.831 0.96347 1.38 80 68
HE AD ≥16 years 0.833 1.37 80 68
LE AD ≤13 years 0.816 0.390672 1.5 81 66
HE AD ≥18 years 0.861 1.2 80 73
AUC, area under the curve; AD, Alzheimer disease; LE, lower education; 
HE, higher education.









Whole AD 0.844 –0.403 80 70
LE AD <16 years 0.846 0.943239 –0.405 80 70
HE AD ≥16 years 0.843 –0.403 80 70
LE AD ≤13 years 0.834 0.476093 –0.29 81 66
HE AD ≥18 years 0.870 –0.52 80 74
MMSE, Mini Mental State Examination; AUC, area under the curve; AD, 




















   
   
   
   
   
   
   
   
   
   
























measures of such a multifactorial concept. It should be 
noted, however, that partial validation of the use of years 
of education for this purpose comes from the repeated ob-
servation of an inverse relationship between reserve quan-
tified by this particular surrogate measure and cerebral 
metabolism [4, 17, 18]. Our data are also consistent with 
these observations, measuring higher wMetaROI scores in 
individuals with LE. In addition, none of the more com-
plex indices could be used in clinical practice for reserve-
adjusted diagnostic thresholding. Although we hypothe-
size that our results are not specific to this proxy, further 
studies should be carried out on this subject.
There are possible caveats in our study when interpret-
ing the results. We included normal controls without se-
lection on the basis of amyloid status, using the strategy 
most commonly adopted to define normal reference da-
tasets in imaging. We used a summary metric of metabo-
lism in order to test the impact of reserve on an objective 
and robust index. Previous studies have shown that vi-
sual analyses or visual interpretation of voxelwise outputs 
might be superior to summary metrics for diagnostic pur-
poses [20]. However, the impact of different levels of edu-
cation on the visual interpretation of statistical maps 
would be difficult to estimate given the lack of an objec-
tive cut-off. 
Finally, we studied subjects with dementia and did not 
include patients with prodromal AD, where deviations 
from normality are subtler. This population deserves a 
targeted investigation. 
Conclusion
In conclusion, the present study directly addressed for 
the first time the impact of the reserve phenomenon on 
the diagnostic accuracy of FDG-PET and the normality 
threshold. Although the effect of cognitive reserve was 
confirmed in the present group of highly educated pa-
tients, the use of an education-adjusted threshold did not 
significantly impact the diagnostic accuracy of FDG-PET, 
which was equally high in the whole population and in 
the LE and HE subgroups. 
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